Kiora Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies (Tables)

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2019

Summary of Significant Accounting Policies

Schedule of unvested restricted common stock and potential common stock equivalents are not included in the calculation of diluted net loss per share


		Year Ended December 31,
		2019		2018
Common Stock Warrants		2,875,006		2,722,967
Employee Stock Options		174,175		138,324
Preferred Stock		852,500		852,500
Total Shares of Common Stock Issuable		3,901,681		3,713,791

Schedule of changes in the contract liabilities


		December 31,			December 31,
		2019			2018
Contract Liabilities:
Deferred Revenue		$	(2,686,000)		$	2,686,000


		Twelve
		Months Ended
		December 31,
		2019
Revenue recognized in the period from:
Amounts included in contract liability at the beginning of the period		$	2,686,000